Jennifer A. Minnix, Ph.D.
Department of Behavioral Science, Division of Cancer Prevention and Population Sciences
About Dr. Minnix
Dr. Minnix is an Associate Professor in the Department of Behavioral Science at the University of Texas MD Anderson Cancer Center, and the Research Director of Tobacco Research and Treatment Program (TRTP). As a clinical psychologist, she is particularly interested in furthering the understanding of the affective processes related to nicotine use and believes that the study of individual differences resulting from and/or leading to chronic nicotine use offers a promising line of inquiry. She helps to expand the TRTP’s multidisciplinary approach to the study of nicotine and tobacco use, including future tailored treatment strategies based on individual genetic markers, neural and other biological biomarkers, and individual differences in use, affect, and dependence. She has extensive expertise in the implementation, tailoring, fidelity, and quality of behavioral health interventions for tobacco cessation. Dr. Minnix has been an integral investigator/ co-investigator on more than 15 NIH, CPRIT, and industry-sponsored clinical trials and programs for smoking cessation with a variety of vulnerable populations including pregnant women, cancer patients and survivors, high-risk smokers eligible for lung cancer screening, and individuals with behavioral health disorders, providing her with a substantial foundation in the science, ethical considerations, and implementation of tobacco use treatment studies and programs. She served as a steering committee member and previous co-chair of NCI’s SCALE (Smoking Cessation and Lung Cancer Screening) collaborative and is the faculty co-lead for the MD Anderson Quitline, a tobacco treatment clinical service designed to disseminate the highly successful, state-of-the-art, and empirically supported clinical model of MD Anderson’s TRTP to underserved community populations. Dr. Minnix received her Ph.D. in Clinical Psychology from Florida State University in 2005 and completed her clinical internship at Baylor College of Medicine in Houston, Texas.
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Behavioral Science, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2005 | Florida State University, Tallahassee, Florida, US, Clinical Psychology, Ph.D |
| 2002 | Florida State University, Tallahassee, Florida, US, Clinical Psychology, M.S |
| 2000 | The University of Texas, Austin, Austin, Texas, US, Psychology, BA |
Postgraduate Training
| 2005-2008 | Postdoctoral Fellowship, Department of Behavioral Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2004-2005 | Clinical Internship, Psychology, Baylor College of Medicine, Houston, Texas |
Experience & Service
Academic Appointments
Assistant Professor, Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2020
Instructor, Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2010
Administrative Appointments/Responsibilities
Research Director, Tobacco Treatment Program, Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, 2018 - Present
Other Appointments/Responsibilities
Smoking Cessation at Lung Examination: The SCALE Collaboration - Steering Committee Co-chair, National Cancer Institute (NCI), Bethesda, MD, 2021 - 2022
Smoking Cessation at Lung Examination: The SCALE Collaboration - Steering Committee Member, National Cancer Institute (NCI), Bethesda, MD, 2016 - 2021
Consultant, The Menninger Department of Psychiatry and Behavioral Sciences, Houston, Texas, 2005 - 2007
Institutional Committee Activities
Chair, Institutional Review Board (IRB 4), 2021 - Present
Vice-chair, Institutional Review Board (IRB 4), 2016 - 2021
Member, Behavioral Science Junior Faculty Committee, 2016 - Present
Associate Member, Institutional Review Board (IRB 3); Executive IRB, 2016 - 2023
Member, The University of Texas MD Anderson Psychologists Committee, 2016 - Present
Member, Eliminate Tobacco Use Initiative Workgroup; Cancer Prevention Platform, 2014 - Present
Faculty Senate Representative and Committee Member, Women's Faculty Program, 2014 - 2015
Member, Lung Cancer Moon Shot / Adult Cessation Steering Committee, 2013 - Present
Member, Institutional Review Board (IRB 4), 2011 - 2016
Member, Faculty Senate, 2009 - 2017
Honors & Awards
| 2006 - 2016 | Loan Repayment Program, National Institutes of Health |
| 2002 | Student Research Award, American Psychological Society |
| 2002 | Student Research Award, Society for Psychophysiological Research |
| 2000 | College Teaching Fellowship, Florida State University |
| 1997 - 2000 | Golden Key Honor Society, The University of Texas |
| 1996 - 2000 | National Dean's List, The University of Texas |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Cinciripini, PM, Minnix, JA, Kypriotakis, G, Erasmus, JJ, Beneventi, DM, Karam-Hage, M, Carpenter, K, Volk, R, Carter, B, Godoy, M, Strange, CD, Shih, YT, Cui, Y, Green, CE, Robinson, JD. Smoking Cessation Interventions in the Lung Cancer Screening Setting. JAMA Internal Medicine 185(3):284-291, 2025. e-Pub 2025. PMID: 39804633.
- Robinson, JD, Cui, Y, Kypriotakis, G, Engelmann, JM, Karam-Hage, M, Minnix, JA, Green, CE, Shete, S, Hatsukami, D, Donny, EC, Murphy, SE, Hecht, SS, Eissenberg, T, Wetter, DW, Cinciripini, PM. Evaluating the Human Abuse Potential of Concurrent Use of Electronic Cigarettes and Low Nicotine Cigarettes Among Adults Who Smoke. Experimental and clinical psychopharmacology 33(2):133-144, 2024. e-Pub 2024. PMID: 39541521.
- Cinciripini PM, Kypriotakis G, Blalock JA, Karam-Hage M, Beneventi DM, Robinson JD, Minnix JA, Warren GW. Survival Outcomes of an Early Intervention Smoking Cessation Treatment After a Cancer Diagnosis. JAMA Oncol 10(12):1689-1696, 2024. e-Pub 2024. PMID: 39480450.
- Cinciripini PM, Minnix JA, Kypriotakis G, Erasmus J, Beneventi D, Karam-Hage M, Carpenter K, Volk RJ, Carter B, Godoy MCB, Strange C, Shih YCT, Cui Y, Green CE, Robinson JD. Smoking Cessation Interventions in the Lung Cancer Screening Setting. JAMA Intern. Med, 2024. e-Pub 2024.
- Rodriguez-Cano R, Kypriotakis G, Robinson JD, Karam-Hage M, Blalock JA, Minnix JA, Beneventi D, Cinciripini PM. Comparing the Fagerstrom Test and Heaviness of Smoking Index in Predicting Smoking Abstinence in Cancer Patients. Nicotine Tob Res 26(11):1576-1581, 2024. e-Pub 2024. PMID: 38785358.
- Robinson JD, Cui Y, Kypriotakis G, Englemann JM, Karam-Hage, Minnix JA, Green CE, Shete S, Hatsukami DK, Donny EC, Murphy SE, Hecht SS, Eissenberg T, Wetter DW, Cinciripini PM. Evaluating the abuse liability of concurrent use of electronic cigarettes and low nicotine cigarettes among adults who smoke. Exp Clin Psychopharmacol, 2024. e-Pub 2024.
- Cinciripini PM, Green CE, Shete S, Minnix JA, Robinson JD, Cui Y, Kim S, Kypriotakis G, Beneventi D, Blalock JA, Versace F, Karam-Hage M. Smoking Cessation After Initial Treatment Failure With Varenicline or Nicotine Replacement: A Randomized Clinical Trial. JAMA 331(20):1722-1731, 2024. e-Pub 2024. PMID: 38696203.
- Kypriotakis G, Kim S, Karam-Hage M, Robinson JD, Minnix JA, Blalock JA, Cui Y, Beneventi D, Kim B, Pan IW, Shih YT, Cinciripini PM. Examining the Association between Abstinence from Smoking and Healthcare Costs Among Patients with Cancer. Cancer Prev Res (Phila) 17(5):217-225, 2024. e-Pub 2024. PMID: 37940143.
- Robinson JD, Kypriotakis G, Karam-Hage M, Cui Y, Beneventi D, Blalock JA, Minnix JA, Cinciripini PM. Brief report: Characterization of electronic cigarette use among patients of a comprehensive cancer center. Am J Addict 33(3):339-342, 2024. e-Pub 2024. PMID: 37807121.
- Cui Y, Robinson JD, Kypriotakis G, Minnix JA, Green CE, Kim S, Karam-Hage M, Cinciripini PM. Comparable cigarette consumption data collected using timeline follow-back and digital diary among treatment-seeking smokers. Psychol Addict Behav 38(3):315-322, 2024. e-Pub 2024. PMID: 37747518.
- Kypriotakis G, Cinciripini PM, Green C, Lawrence D, Anthenelli RM, Minnix JA, Beneventi D, Morris C, Karam-Hage M, Blalock JA. The effects of varenicline, bupropion, nicotine patch and placebo on treating smoking among persons with current or past major depressive disorder: Secondary analysis of a double-blind, randomized, placebo-controlled trial. Am J Psychiatry, 2024. e-Pub 2024.
- Lopez-Olivo MA, Michaud K, Schumacher R, Minnix J, Cinciripini P, Suarez-Almazor ME. Smoking cessation patterns, usefulness of quitting methods, and tobacco cessation motivators and barriers to quit in patients with rheumatoid arthritis. Clin Rheumatol 42(8):2053-2068, 2023. e-Pub 2023. PMID: 37093403.
- Lowenstein LM, Shih YT, Minnix J, Lopez-Olivo MA, Maki KG, Kypriotakis G, Leal VB, Shete SS, Fox J, Nishi SP, Cinciripini PM, Volk RJ. A protocol for a cluster randomized trial of care delivery models to improve the quality of smoking cessation and shared decision making for lung cancer screening. Contemp Clin Trials 128:107141, 2023. e-Pub 2023. PMID: 36878389.
- Cinciripini, PM, Minnix, JA, Robinson, JD, Kypriotakis, G, Cui, Y, Blalock, J, Lam, CY, Wetter, DW. The Effects of Scheduled Smoking Reduction and Precessation Nicotine Replacement Therapy on Smoking Cessation. JMIR Formative Research 7, 2023. e-Pub 2023. PMID: 37338956.
Selected Presentations & Talks
National Presentations
- 2025. Examining Provider-Level Factors and Implementation Preconditions for Evidence-Based Policies and Procedures to Enact Systems Change in Opioid Treatment Programs to Address Disproportionately High Tobacco Use. Conference. Poster presented at the Society for Research on Nicotine and Tobacco (SRNT). Atlanta, Georgia, US.
- 2025. Optimizing the Effectiveness of Tobacco Treatment in the Low-Dose CT Lung Cancer Screening Setting: A Randomized Clinical Trial. Conference. Society for Research on Nicotine and Tobacco (SRNT). New Orleans, Louisiana, US.
- 2024. Optimizing the Effectiveness of Tobacco Treatment in the Low-Dose CT Lung Cancer Screening Setting: A Randomized Clinical Trial. Conference. American Cancer Society National Lung Cancer Roundtable (ACS NLCRT). Atlanta, Georgia, US.
- 2024. FTCD VS HSI Which Measure Of Dependence More Accurately Predicts Smoking Abstinence Among Cancer Patients Undergoing Smoking Cessation Treatment In A Comprehensive Cancer Center?. Conference. Poster presented at the Society for Research on Nicotine and Tobacco (SRNT). Edinburgh, Scotland, GB.
- 2024. Utilization and reliability of smartphone-enabled carbon monoxide devices in a remote smoking cessation trial. Conference. Poster presented at the Society for Research on Nicotine and Tobacco (SRNT). Edinburgh, Scotland, GB.
- 2024. Project Luna: Optimizing The Effectiveness Of A Smoking Cessation Intervention In The Low-Dose Ct Lung Cancer Screening Setting. Conference. Poster presented at the Society for Research on Nicotine and Tobacco (SRNT). Edinburgh, Scotland, GB.
- 2024. The Effect Of Smoking Cessation Following A Cancer Diagnosis On Survival. Conference. Society for Research on Nicotine and Tobacco (SRNT). Edinburgh, Scotland, GB.
- 2023. The Relationships of Childhood Trauma and Post-Traumatic Stress Disorder to Smoking Outcomes in Cancer Patients. Conference. Poster presented at the Society for Research on Nicotine and Tobacco (SRNT). San Antonio, TX, US.
- 2023. The Effect of Anxiety Disorders on Smoking Cessation in Cancer Patients. Conference. Poster presented at the Society for Research on Nicotine and Tobacco (SRNT). San Antonio, Texas, US.
- 2023. Cross-validation of smoking consumption collections using timeline follow-back and digital diary. Conference. Poster presented at the Society for Research on Nicotine and Tobacco (SRNT). San Antonio, TX, US.
- 2021. Treatment Fidelity in Behavioral Tobacco Cessation Trials – Scoping Review and Measurement Recommendations. Conference. Poster presented at the annual meeting of the Society for Research on Nicotine and Tobacco. Virtual, US.
- 2020. Recruitment of Long-term, Older Smokers to Smoking Cessation Trials in the Lung Screening Setting: Understanding Who is Declining Participation & Why. Conference. Poster presented at the annual meeting of the Society for Research on Nicotine and Tobacco. Virtual, US.
- 2019. Using a Neuroaffective Biomarker to Match Smokers to Either Varenicline or Nicotine Patch Treatment. Conference. Society for Research on Nicotine and Tobacco. San Francisco, CA, US.
- 2019. Evaluating the Impact of Insomnia on the Ability to Quit Smoking. Conference. Poster presented at the Society for Research on Nicotine and Tobacco Annual Meeting. San Francisco, CA, US.
- 2019. The Effects of Varenicline, Bupropion, Nicotine Patch, and Placebo on Cessation among Smokers with Current and Past Major Depression. Conference. Society for Research on Nicotine and Tobacco. San Francisco, CA, US.
- 2019. The Effects of Varenicline, Bupropion, Nicotine Patch, and Placebo on Cessation and Neuropsychiatric Adverse Events among Smokers with Recurrent or Single Episode Major Depressive Disorder. Conference. Poster presented at the Society for Research on Nicotine and Tobacco Annual Meeting. San Francisco, CA, US.
- 2018. To screen or not to screen? Does testing positive for THC affect amplitude modulation of the LPP?. Conference. Vanderbilt Center for Addiction Research, 2nd Annual Science Day. Nashville, TN, US.
- 2018. Using a Neuroaffective Biomarker to Match Smokers to Treatment: Results From a New Clinical Trial. Conference. BioScience Research Collaborative, 2nd Annual Alcohol and addiction Research Symposium. Houston, TX, US.
- 2013. Affective ratings of cigarette-related, emotional, and neutral images in current smokers, smokers receiving smoking cessation treatment, and never smokers. Conference. Poster presented at the annual meeting of the Society for Research on Nicotine and Tobacco. Boston, MA, US.
- 2012. Alpha Oscillations in Response to Affective and Cigarette-Related Stimuli in Smokers. Conference. Poster presented at the Society for Research on Nicotine and Tobacco Annual Meeting. Houston, TX, US.
- 2012. Brain Responses to Pleasant Stimuli Predict Smoking Abstinence. Conference. Poster presented at the Society for Research on Nicotine and Tobacco Annual Meeting. Houston, TX, US.
- 2012. The Relationship of Cue-Modulated Acoustic Startle Response to Smoking Cessation Pharmacotherapy Outcome. Conference. Society for Research on Nicotine and Tobacco Annual Meeting. Houston, TX, US.
- 2012. Evaluation of Mediators of an Intensive Depression-Focused Intervention for Pregnant Smokers Using Mediated Moderation Analysis. Conference. Poster Presented at Society for Research on Nicotine and Tobacco Annual Meeting. Houston, TX, US.
- 2010. Event Related Potentials to Cigarette-Related and Intrinsically Motivating Stimuli. Conference. Nora D. Volkow Presentation and The Second Annual Texas Lab Exchange. Galveston, TX, US.
- 2008. Startle probe P3 amplitude when looking at cigarette cues. Conference. Poster presented at the 14th annual meeting of the Society for Research on Nicotine and Tobacco. Portland, OR, US.
- 2007. Self-efficacy Mediates the Effect of Depression on Smoking Susceptibility in Adolescents. Conference. Poster presented at the 13th annual meeting of the Society for Research on Nicotine and Tobacco. Austin, TX, US.
- 2006. The Change in Resolved Plans and Suicidal Ideation Factors of Suicide after Participation in an Intensive Outpatient Treatment Program. Conference. Poster presented at the annual meeting for Division 12 of the American Psychological Association. New Orleans, LA, US.
- 2006. The DRD2 Taq1-B Polymorphism and Its Relationship to Smoking Abstinence. Conference. Poster presented at the annual meeting of the Society for Research on Nicotine and Tobacco. Orlando, FL, US.
- 2006. Nicotine differentially inhibits the acoustic startle reflex of African American and White smokers. Conference. Poster presented at the 12th annual meeting of the Society for Research on Nicotine and Tobacco. Orlando, FL, US.
- 2006. The serotonin transporter gene and affective processing of emotional cues during nicotine deprivation. Conference. Poster presented at the 12th annual meeting of the Society for Research on Nicotine and Tobacco. Orlando, FL, US.
- 2002. Reassurance seeking and left frontal hypoactivation as interactive diatheses for depression. Conference. Poster presented at the 14th annual meeting of the American Psychological Society. New Orleans, LA, US.
- 2002. Reassurance-Seeking and Frontal EEG Asymmetry as Interactive Diatheses for Depressive Symptoms in Clinical and College Student Populations. Conference. Poster presented at the 42nd annual meeting of the Society for Psychophysiological Research. Washington, D.C, US.
- 2002. A new application: Cognitive behavioral analysis system of psychotherapy applied to the treatment of couples. Conference. Poster presented at the 36th annual meeting of the Association for Advancement of Behavior Therapy. Reno, NV, US.
International Presentations
- 2017. Differences Between Male and Female Smokers in Brain Responses to Cigarette-Related and Emotional Stimuli. Conference. Poster presented at the 57th annual meeting of the Society for Psychophysiological Research. Minneapolis, AT.
- 2017. Characterization of Behavioral Therapy Duration Thresholds for Effective Abstinence Responses in Smokers. Conference. Annual meeting for the Society for Research on Nicotine and Tobacco. Florence, IT.
- 2014. Cognitive Reappraisal in Deprived and Non-Deprived Smokers. Conference. Society for Psychophysiological Research. Florence, IT.
- 2009. Event Related Potentials to Cigarette-Related and Intrinsically Motivating Stimuli. Conference. 49th Annual Society for Psychophysiological Research Meeting. Berlin, DE.
- 2008. Startle Probe P3 Amplitude When Viewing Cigarette Cues. Conference. Poster presented at the 10th Annual Conference of SRNT Europe. Rome, IT.
- 2001. Emotional lability predicts variability in frontal EEG asymmetry. Conference. Poster presented at the 41st annual meeting of the Society for Psychophysiological Research. Montreal, CA.
- 2001. Emotional lability predicts variability in frontal EEG asymmetry. Conference. Poster session presented at the 13th annual meeting of the American Psychological Society. Toronto, CA.
Formal Peers
- 2015. Tobacco Use Disorder: Epidemiology, Biology and treatment. Visiting. Houston, TX, US.
- 2011. Affect, Nicotine Dependence, and Emotion Regulation. Invited. Charleston, SC, US.
Grant & Contract Support
| Date: | 2025 - 2030 |
| Title: | Leveraging Quitline Community to Increase Lung Cancer Screening Among Quitline Participants |
| Funding Source: | National Institutes of Health |
| Role: | PI |
| ID: | 1R01CA296018-01A1 |
| Date: | 2025 - 2028 |
| Title: | OUTPACE Tobacco: Scaling Up Tobacco-Free Workplace Initiatives in Texas Opioid Treatment Centers |
| Funding Source: | CANCER PREVENTION RESEARCH INST OF TX |
| Role: | Co-I |
| ID: | PP260002 |
| Date: | 2025 - 2030 |
| Title: | Guideline Concordant Care for Lung Cancer Screening: Testing a Practical Implementation Approach for the Real World |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | Co-I |
| ID: | 1R01CA303308-01 |
| Date: | 2024 - 2027 |
| Title: | A Virtual, Centralized Lung Cancer Screening Program for Northeast Texas |
| Funding Source: | Cancer Prevention Research of Texas |
| Role: | PI |
| ID: | PP250004 |
| Date: | 2024 - 2029 |
| Title: | The Impact of Switching Smoking Cessation Treatment Non-Responders to High-Dose Rescue Pharmacotherapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01-CA2899050 |
| Date: | 2024 - 2026 |
| Title: | A Virtual, Centralized Lung Cancer Screening Program for Northeast Texas |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | PP240007 |
| Date: | 2024 - 2028 |
| Title: | Comparative Effectiveness of Sequential Pharmacotherapeutic Strategies and Virtually Delivered Treatment to Optimize Smoking Cessation |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA278938-01A1 |
| Date: | 2023 - 2028 |
| Title: | MD Anderson Community Cessation (MDACC) Quitline: Advancing Equity in Community Health Through High-Value, Cost-Efficient Cancer Prevention Interventions |
| Funding Source: | MDACC Permanent Health Funds |
| Role: | Co-I |
| Date: | 2023 - 2028 |
| Title: | The University of Texas MD Anderson Cancer Center Tobacco Research & Treatment Program |
| Funding Source: | MDACC Permanent Health Funds |
| Role: | Co-I |
| Date: | 2023 - 2028 |
| Title: | RA-Quitline: A tailored, multi-faceted tobacco cessation intervention for patients with rheumatoid arthritis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA285983-01 |
| Date: | 2023 - 2026 |
| Title: | Taking Texas Tobacco Free: Dissemination to and Implementation within Lung Cancer Screening Programs |
| Funding Source: | CPRIT |
| Role: | Co-PI |
| ID: | PP230002 |
| Date: | 2022 - 2029 |
| Title: | Comparative Effectiveness of Virtually Delivered Sequential Smoking Cessation Treatment |
| Funding Source: | PCORI |
| Role: | Co-I |
| ID: | 25026 |
| Date: | 2022 - 2024 |
| Title: | Smartphone-Delivered Scheduled Smoking with Biochemical Monitoring as an Adjunct Cessation Therapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R21DA055765-01 |
| Date: | 2021 - 2023 |
| Title: | Improving the Quality of Smoking Cessation and Lung Cancer Screening among Primary Care Patients |
| Funding Source: | UTH-MDA Population Health Initiative Collaborative Projects Fund |
| Role: | Co-I |
| Date: | 2021 - 2028 |
| Title: | Comparative Effectiveness of Virtually Delivered Sequential Smoking Cessation Treatment |
| Funding Source: | PCORI |
| Role: | Co-I |
| ID: | 21272 |
| Date: | 2020 - 2022 |
| Title: | Expanding the reach of University of Texas MD Anderson Cancer Center Tobacco Treatment Program |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | P30 CA016672-44S6 |
| Date: | 2020 - 2023 |
| Title: | Tobacco Outreach and Education Program, Texas Quit Vaping Program for Youth: This Is Quitting |
| Funding Source: | MDACC Tobacco Settlement Funds |
| Role: | PI |
| Date: | 2020 - 2023 |
| Title: | Expanding MD Anderson Quitline Service to Critically Underserved Populations in Texas |
| Funding Source: | MDACC Tobacco Settlement Funds |
| Role: | Co-I |
| Date: | 2019 - 2023 |
| Title: | Genetic substrates of a novel neural biomarker for smoking cessation |
| Funding Source: | AACR-Johnson & Johnson Lung Cancer Innovation Science Grant |
| Role: | Co-I |
| ID: | AACR 667756 |
| Date: | 2019 - 2024 |
| Title: | Project PISCES-Precision Implemented Smoking Cessation Evaluation Study |
| Funding Source: | MDACC Moonshot Donor Funds |
| Role: | Co-I |
| ID: | MDACC Lung Moonshot Prevention Platform |
| Date: | 2019 - 2021 |
| Title: | Stress-Based Smoking Cessation for Latinx Smokers |
| Funding Source: | Duncan Family Institute for Cancer Prevention and Risk Assessment and UHAND (University of Houston/The University of Texas MD Anderson Cancer Center) Partnership: Cancer Prevention Disparities Seed-funding Research Program |
| Role: | Co-PI |
| Date: | 2019 - 2020 |
| Title: | Mobile App for a Positive Psychology Intervention to Enhance Smoking Cessation Outcomes |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator-MDACC |
| ID: | 1-R43-CA217428-01 |
| Date: | 2019 - 2024 |
| Title: | Improving the Quality of Smoking Cessation and Shared Decision Making for Lung Cancer Screening: A Cluster Randomized Trial |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP190210 |
| Date: | 2018 - 2023 |
| Title: | The impact of nicotine product switching on use, toxicant exposure, and biomarkers of risk on smoking-related chronic medical illness |
| Funding Source: | NIH/NHLBI |
| Role: | Co-I |
| ID: | U54HL143031 |
| Date: | 2018 - 2019 |
| Title: | Mobile App for Behavioral Activation in Smoking Cessation with Elevated Depressive Symptom Smokers |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator-MDACC |
| ID: | 1R43CA206682-01A1 |
| Date: | 2016 - 2023 |
| Title: | Optimizing Effectiveness of Smoking Cessation Invention During LDCT Screening for Lung Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA207078-01 |
| Date: | 2016 - 2019 |
| Title: | Evaluating Concomitant Use of Very Low Nicotine Content Cigarettes and E-Cigarettes Among Daily and Non-Daily Smokers on Abuse Liability |
| Funding Source: | NIH/FDA |
| Role: | Co-I |
| ID: | 1 R01 DA042526-01 |
| Date: | 2015 - 2019 |
| Title: | Improving Service Delivery for Cancer Survivors in Primary Care Settings |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | PP160027 |
| Date: | 2015 - 2019 |
| Title: | Low reward sensitivity and behavioral activation therapy for smoking cessation |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R34DA037391-01A1 |
| Date: | 2015 - 2016 |
| Title: | A Phase 4, randomized, double-blind, active and placebo-controlled, multicenter study evaluating the neuropsychiatric safety and efficacy of 12 weeks varenicline tartrate 1mg BID for smoking cessation in subjects with and without a history of psychiatric disorders |
| Funding Source: | Pfizer Inc |
| Role: | Collaborator |
| ID: | CS2011-00035609LK 01 |
| Date: | 2015 - 2020 |
| Title: | Varenicline and Combined NRT for Initial Smoking Cessation and Rescue Treatment in Smokers: A Randomized Pilot Trial |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP150228 |
| Date: | 2014 - 2018 |
| Title: | Intrinsic reward sensitivity & smoking cessation with varenicline or patch NRT |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP140262 |
| Date: | 2013 - 2019 |
| Title: | Personalized Smoking Cessation and Reduction in Adult Smokers: A Double-Blind, Randomized Clinical Trial |
| Funding Source: | MDACC Moon Shot Donor Funds |
| Role: | Co-I |
| ID: | MDACC Lung Moon Shot Platform Prevention |
| Date: | 2011 - 2016 |
| Title: | Suppression of negative affect indexed by the late positive potential in smokers attempting to quit |
| Funding Source: | NIH/NIDA |
| Role: | PI |
| ID: | R00-DA025181-03 |
| Date: | 2010 - 2015 |
| Title: | Pharmacogenetics of nicotine addiction treatment |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 2-U01-DA020830-06 |
| Date: | 2010 - 2015 |
| Title: | New pharmacotherapy for alcohol and co-morbid disorders |
| Funding Source: | NIH/NIAAA |
| Role: | Collaborator |
| ID: | 5R01AA019720-05 |
| Date: | 2009 - 2011 |
| Title: | Preliminary effectiveness and safety of bupropion to promote smoking cessation during pregnancy |
| Funding Source: | Center for Clinical and Translational Sciences (CCTS) |
| Role: | Co-I |
| ID: | CCTS T2 MRP |
| Date: | 2009 - 2015 |
| Title: | Effectiveness of varenicline plus bupropion for smoking cessation |
| Funding Source: | NIH/NIDA |
| Role: | Collaborator |
| ID: | 1R01DA024709-01A2 |
| Date: | 2009 - 2011 |
| Title: | Suppression of negative affect indexed by the late positive potential in smokers |
| Funding Source: | NIH/NIDA |
| Role: | PI |
| ID: | 1K99DA025181-01A1 |
| Date: | 2005 - 2008 |
| Title: | Affective modulation of negative affect in response to nicotine administration (competitively awarded through an external review process) |
| Funding Source: | NIH/NCI |
| Role: | Trainee |
| ID: | R25CA57730 |
| Date: | 2004 - 2012 |
| Title: | Pharmacogenetics, emotional reactivity and smoking |
| Funding Source: | NIH/NIDA |
| Role: | Collaborator |
| ID: | 1R01DA017073-01 |
| Date: | 2003 - 2010 |
| Title: | A mood management intervention for pregnant smokers |
| Funding Source: | NIH/NIDA |
| Role: | Collaborator |
| ID: | 1R01 DA014301-01 |
Patient Reviews
CV information above last modified July 11, 2025